Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SSY Group ( (HK:2005) ) has issued an update.
SSY Group Limited has announced the approval of three bulk drugs—Fenofibrate, Choline Fenofibrate, and Levornidazole Disodium Phosphate—by China’s National Medical Products Administration. These approvals enhance the company’s product offerings in the treatment of hyperlipidemia, hypercholesterolemia, and severe infections, potentially strengthening its market position and benefiting stakeholders by expanding its portfolio in the Chinese pharmaceutical market.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of bulk drugs. The company specializes in products used for treating hyperlipidemia, hypercholesterolemia, and severe infections, with a market focus on China.
YTD Price Performance: -8.80%
Average Trading Volume: 14,342,383
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.15B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.